1 2	State of Arkansas 90th General Assembly	A Bill	
3	Regular Session, 2015		SENATE BILL 959
4			
5	By: Senator D. Sanders		
6			
7		For An Act To Be Entitled	
8	AN ACT TO	PROMOTE HEALTHCARE TRANSPARENCY;	TO
9	PRESERVE THE INTEGRITY OF THE RELATIONSHIP BETWEEN		
10	HEALTHCARE	E PROVIDERS AND PATIENTS; TO PROHI	BIT GIFTS
11	TO HEALTHO	CARE PROVIDERS; TO CREATE THE PROV	'IDER-
12	PATIENT RE	LATIONSHIP PROTECTION ACT OF 2015	; AND FOR
13	OTHER PURE	OSES.	
14			
15			
16		Subtitle	
17	TO C	REATE THE PROVIDER-PATIENT	
18	RELA	TIONSHIP PROTECTION ACT OF 2015.	
19			
20	WHEREAS, the Sta	ate of Arkansas and its healthcare	providers are
21	dedicated to preserving	ng the integrity of the provider-p	atient relationship
22	and are committed to t	the ethical service of patients wh	o entrust their care
23	to licensed healthcare	e professionals; and	
24			
25	_	s expect that decisions about the	
26	• •	onsiderations, patient need, and r	•
27	of effectiveness as re	eflected by the applicable standar	d of care; and
28			
29	· · · · · · · · · · · · · · · · · · ·	ovider-patient relationship is par	<u>-</u>
30		eir patients any conflicts of inte	
31	-	at that preserves the provider rel	ationship with
32	patients; and		
33			-
34		ctions on gifts and increased tran	
35	•	sumers, businesses, and the state	
36	promotion of expensive	e prescription drugs and medical d	levices,

1			
2	NOW THEREFORE,		
3	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:		
4			
5	SECTION 1. Arkansas Code Title 17, Chapter 80, is amended to add an		
6	additional subchapter to read as follows:		
7	Subchapter 4 - Arkansas Provider-Patient Relationship Protection Act of 201		
8			
9	17-80-401. Title.		
10	This act shall be known and may be cited as the "Arkansas Provider-		
11	Patient Relationship Protection Act of 2015".		
12			
13	17-80-402. Legislative intent.		
14	It is the intent of the General Assembly to increase transparency and		
15	reduce real or perceived conflicts of interest which undermine patient		
16	confidence in healthcare providers and increase healthcare costs.		
17			
18	17-80-403. Definition.		
19	As used in this subchapter:		
20	(1) "Allowable expenditures" means:		
21	(A) Professional samples of prescription drugs provided to		
22	a healthcare provider for free distribution to patients;		
23	(B) Items with a total combined retail value, in any		
24	calendar year, of no more than twenty-five dollars (\$25.00);		
25	(C) A payment to the sponsor of a medical conference,		
26	professional meeting, or other educational program, provided that the payment		
27	is not made directly to a healthcare provider and is used solely for bona		
28	fide educational purposes;		
29	(D) Reasonable honoraria and reimbursement of reasonable		
30	expenses of a healthcare provider who serves on the faculty at a professional		
31	or educational conference or meeting;		
32	(E) Compensation for the professional or consulting		
33	services of a healthcare provider in connection with a genuine research		
34	product that constitutes systematic investigation, is designed to develop or		
35	contribute to general knowledge, and can reasonably be considered to be of		
36	significant interest or value to researchers or healthcare providers working		

1	in the particular field of industry;		
2	(F) As described in a written agreement between the		
3	healthcare provider and medical device manufacturer, reimbursement for		
4	reasonable expenses necessary for technical training of a healthcare provider		
5	on the use of a medical device;		
6	(G) Provision of or payment for modest meals and		
7	refreshments in connection with educational presentations for the purposes of		
8	educating and informing healthcare providers about the benefits, risks, and		
9	appropriate uses of prescription drugs or medical devices, disease states or		
10	other scientific information, provided that the presentations occur in a		
11	venue and manner conducive to informational communication;		
12	(H) Royalties and licensing fees paid to a healthcare		
13	provider in return for contractual rights to use or purchase a patented or		
14	otherwise legally recognized discovery for which the healthcare provider		
15	holds an ownership right;		
16	(I) Publications and educational materials; and		
17	(J) Salaries or other benefits paid to employees;		
18	(2) "Gift" means any payment, entertainment, advance, services,		
19	or anything of value unless consideration of equal or greater value has been		
20	given but does not include allowable expenditures; and		
21	(3) "Healthcare provider" means an individual or entity licensed		
22	by the state to provide healthcare services.		
23			
24	17-80-404. Gifts to healthcare providers prohibited.		
25	It shall be unlawful for any pharmaceutical, biomedical, or medical		
26	device manufacturer or distributor doing business in the state, or any agent		
27	thereof, to offer or give a gift to a healthcare provider, a healthcare		
28	provider's spouse, or a healthcare provider's staff or practice, whether		
29	incorporated or unincorporated.		
30			
31	17-80-405. Transparency of allowable expenditures.		
32	(a) Annually on or before April 1 of each calendar year, a		
33	pharmaceutical, biomedical, or medical device manufacturer doing business in		
34	the state shall disclose to the office of the Attorney General in the		
35	preceding calendar year the product marketing costs in the state and the		
36	value, nature, and recipient information of any allowable expenditure to a		

1	healthcare provider, a spouse of a healthcare provider, or the staff or		
2	practice, regardless of incorporation, of a healthcare provider.		
3	(b) A healthcare provider shall annually disclose in a written		
4	document to patients:		
5	(1) The value and nature of compensation received for allowable		
6	expenditures, affiliations with payers or other healthcare providers;		
7	(2) Participation in accountable care organizations or similar		
8	entities that create incentives for patients to seek care inside the		
9	organization;		
10	(3) Ownership or financial interests in healthcare businesses,		
11	including without limitation hospitals, imaging centers, laboratories,		
12	equipment vendors, or physical therapy clinics;		
13	(4) Consulting services including allowable expenditures;		
14	(5) Adverse actions taken by the licensure board or agency		
15	authorized to license and regulate the healthcare provider to the extent such		
16	actions are not classified as confidential under state law; and		
17	(6) Adjudicated civil or criminal actions related to federal or		
18	state healthcare fraud and abuse.		
19	(c) A healthcare provider shall disclose the goals of the clinical		
20	trial and the optimal clinical outcomes to patients before the patient agrees		
21	to participate in clinical trials.		
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			